Endovascular stent-based revascularization of malignant superior vena cava syndrome with concomitant implantation of a port device using a dual venous approach

Susanne Anton*, T. Oechtering, E. Stahlberg, F. Jacob, M. Kleemann, J. Barkhausen, J. P. Goltz

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Purpose: The aim of this paper is to evaluate the safety and efficacy of endovascular revascularization of malignant superior vena cava syndrome (SVCS) and simultaneous implantation of a totally implantable venous access port (TIVAP) using a dual venous approach. Materials and methods: Retrospectively, 31 patients (mean age 67 ± 8 years) with malignant CVO who had undergone revascularization by implantation of a self-expanding stent into the superior vena cava (SVC) (Sinus XL®, OptiMed, Germany; n = 11 [Group1] and Protégé ™ EverFlex, Covidien, Ireland; n = 20 [Group 2]) via a transfemoral access were identified. Simultaneously, percutaneous access via a subclavian vein was used to (a) probe the lesion from above, (b) facilitate a through-and-through maneuver, and (c) implant a TIVAP. Primary endpoints with regard to the SVC syndrome were technical (residual stenosis < 30%) and clinical (relief of symptoms) success; with regard to TIVAP implantation technical success was defined as positioning of the functional catheter within the SVC. Secondary endpoints were complications as well as stent and TIVAP patency. Results: Technical and clinical success rate were 100% for revascularization of the SVS and 100% for implantation of the TIVAP. One access site hematoma (minor complication, day 2) and one port-catheter-associated sepsis (major complication, day 18) were identified. Mean catheter days were 313 ± 370 days. Mean imaging follow-up was 184 ± 172 days. Estimated patency rates at 3, 6, and 12 months were 100% in Group 1 and 84, 84, and 56% in Group 2 (p = 0.338). Conclusion: Stent-based revascularization of malignant SVCS with concomitant implantation of a port device using a dual venous approach appears to be safe and effective.

OriginalspracheEnglisch
ZeitschriftSupportive Care in Cancer
Jahrgang26
Ausgabenummer6
Seiten (von - bis)1881-1888
Seitenumfang8
ISSN0941-4355
DOIs
PublikationsstatusVeröffentlicht - 01.06.2018

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Biomedizintechnik
  • Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)

DFG-Fachsystematik

  • 205-14 Hämatologie, Onkologie
  • 205-30 Radiologie, Nuklearmedizin, Strahlentherapie, Strahlenbiologie
  • 205-32 Medizinische Physik, Biomedizinische Technik

Fingerprint

Untersuchen Sie die Forschungsthemen von „Endovascular stent-based revascularization of malignant superior vena cava syndrome with concomitant implantation of a port device using a dual venous approach“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren